Stephanie Sivinski Image

Stephanie Sivinski

is an Associate in the Intellectual Property Litigation Practice Groups in the Dallas office of Haynes and Boone, LLP. Her intellectual property and commercial litigation practice focuses on complex intellectual property and commercial disputes in the chemical and life sciences, including representation of generic pharmaceutical companies in Hatch-Waxman litigation. Her practice has also touched on topics as varied as thermodynamics, computer software, and semiconductor manufacturing.

For more information or to contact Stephanie, please visit her Firm Profile Page.

Recent Articles by Stephanie Sivinski

Vanda v. West-Ward: This Time, Dosage Adjustment Claims are Patent Eligible Subject Matter

The Federal Circuit’s decision in Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals, No. 2016-2707, addresses the complicated topic of patent eligibility in the pharmaceutical space. Much of the decision compares Vanda’s claims to those found ineligible for patent protection in the U.S. Supreme Court’s decision in Mayo Collaborative Services v. Prometheus Laboratories, 132 S. Ct. 1289 (2012). While the ultimate patentability conclusions are opposite, the claims in Vanda and Mayo are very similar, highlighting the thin—and often unpredictable—line that divides eligible and ineligible subject matter. Generic drug manufacturers must account for this unpredictability in gauging their litigation risks.